The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Oranskaya A.N.

A.I. Evdokimov Moscow State Medical Stomatological University, Moscow

Biphasic insulin analogs: their potential in the management of type 2 diabetes mellitus

Authors:

Oranskaya A.N.

More about the authors

Journal: Problems of Endocrinology. 2011;57(4): 48‑55

Views: 2578

Downloaded: 27

Download PDF (RU)
Contact the author
Table of contents

BIPHASIC INSULIN ANALOGS: THEIR POTENTIAL IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS
BIPHASIC INSULIN ANALOGS: THEIR POTENTIAL IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS

To cite this article:

Oranskaya AN. Biphasic insulin analogs: their potential in the management of type 2 diabetes mellitus. Problems of Endocrinology. 2011;57(4):48‑55. (In Russ.)

МСФ на ЯМ
Close metadata

Keywords:

biphasic insulin analogs
insulin therapy

Authors:

Oranskaya A.N.

A.I. Evdokimov Moscow State Medical Stomatological University, Moscow

List of references:

  1. Dedov I.I., Shestakova M.V. Inkretiny: novaya vekha v lechenii sakharnogo diabeta 2-go tipa. Prakticheskoe rukovodstvo dlya vrachei. M: Dipak 2010;92.
  2. American Diabetes Association, Diabetic retinopathy. Diabetes Care 2002;25:Suppl 1:S90-S93.
  3. American Diabetes Association, Diabetic nephropathy. Diabetes Care 2002;25:Suppl 1:S85-S89.
  4. Gaede P., Sund-Andersen H., Parving H.H. et al. Effect of multifactorial intervention on mortality in Type 2 diabetes. N Engl J Med 2008;258:580-591.
  5. Diabetes Control and complication trial research Group/ The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
  6. UK Prospective Diabetes Study (UKPDS) Group/ Intensive blood-glucose control with sulphonilureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS). Lancet 1998;352:837-853.
  7. Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. I.I. Dedova, M.V. Shestakovoi. Izd. 4-e. M 2009.
  8. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2009;32:Suppl 1:S13-S16.
  9. Shim W.S., Kim S.K., Kim H.J. Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes. Eur J Endocrinol 2006;155:4:615-622.
  10. Turner R.C., Cull C.A., Frigbi V. et al. For the UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-2012.
  11. Gerich L.E. Arch Int Med 2003;163:1306-1316.
  12. Landgraf R. Diabet Vetab Res Rev 2004;20:Suppl 2:S9-S12.
  13. Owens D.R., Zinman B., Bolli G.B. Lancet 2001;358:739-746.
  14. Gammeltoft S., Hansen B.F., Dideriksen L. et al. Insulin aspart, a novel rapid-acting human insulin analogue. Exp Opin Invest Drugs 1999;8:9:1431-1442.
  15. Kurtzhals P., Schaffer L., Sorensen A. et al. Correlations of receptor binding and metabolic and mitogenic potenticies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005.
  16. Jacobsen L., Bell P., McSorley P. et al. Biphasic insulin aspart and biphasic human insulin in Type 2 diabetes: a comparison. Diabetes 2000;49:Suppl 1:A112.
  17. Riddle M.C. Am J Med 2004;116:Suppl 3A:10S-16S.
  18. Heise T., Heinemann L., Övelmann U.H. et al. Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy 2. Diabetes Care 2009;32:1431-1433.
  19. Garber J., Wahlen J., Wahl T. et al. Attainment of glycaemic goals in type 2 diabetes with once, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006;8:58-66.
  20. Kabadi & Kabadi. Diabetes Res Clin Prac 2006;72:3:265-270.
  21. Raskin et al. Diabetes 2006;55:Suppl 1:131.
  22. Kann P.H., Wascher T. et al. Starting insulin therapy in type 2 diabetes:twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabet 2006;114:9:527-532.
  23. Strojek K., Bebakar Wan M.W., Khutsoane D.T.M. Pesic, Alena Šmahelové, Henrik F. Thomsen, S.Kalra Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs:an open-label, multinational RCT. Curr Med Res Opin 2009;25:12:2887-2894.
  24. et al. Terapiya dvukhfaznym insulinom aspart 30/70 (NovoMiks 30) uluchshaet glikemicheskii kontrol' u patsientov s sakharnym diabetom 2-go tipa: dannye rossiiskoi kogorty patsientov nablyudatel'noi programmy IMPROVE - programmy po izucheniyu bezopasnosti i effektivnosti dvukhfaznogo insulina aspart 30 v rutinnoi klinicheskoi praktike Shestakova M.V., Ballan Akil. Sakharnyi diabet 2010;1:3-10.
  25. Holman R.R., Thorne K.I. et al. 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:17:1716-1730.
  26. Jang H.C., Guler S., Shestakova V. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensifi/cation with a modern premixed insulin help? Result from a subanalysis ofthe PRESENT study. Int J Clin Pract 2008;62:1013-1018.
  27. Liebl A., Prager R., Kaiser M. et al. The PREFER study: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target <7,0%. EASD 2006;Poster 998.
  28. Khutsoane D., Sharma S.K., Almustafa M. et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab 2008;10:212-222.
  29. Lee W.C., Balu S., Cobden D. et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-1725.
  30. Riddle M.C., Schneider J. Beginning insulin treatment of obese patients with evening 30/70 insulin plus glimepiride versus insulin alone. Diabetes Care 1998;21:7:1052-1057.
  31. Boehm B., Home P., Kamp N. et al. Biphasic insulin aspart and biphasic human insulin compared in Type 2 diabetic subjects. Diabetologia 2001;44:Suppl 1:A210.
  32. Boehm B., Home P., Behrend S. et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med 2002;19:5:393-399.
  33. GAO Yan and GUO Xiao-hui Switching from human insulin to biphasic insulin aspart 30 treatment gets more patients with type 2 diabetes to reach target glycosylated hemoglobin <7%: the results from the China cohort of the PRESENT study. Chinese Med J 2010;123:9:1107-1111.
  34. Walid K.H., Fakhoury Hartmut Richter, Torsten E. Christensen Real-Life Dosage and Clinical Efficacy of Biphasic Insulin Preparations in Patients with Type 2 Diabetes/Received: August 24, 2010/Published online: October 11, 2010. Healthcare: Springer 2010.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.